Malvern, PA, United States of America

Hakon Hakonarson

USPTO Granted Patents = 44 

 

 

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 77(Granted Patents)


Location History:

  • Reykjavic, IS (2003)
  • Reykjavik, IS (2005 - 2008)
  • Revkjavik, IS (2008)
  • Malvern, PA (US) (2013 - 2023)

Company Filing History:


Years Active: 2003-2025

Loading Chart...
Loading Chart...
Loading Chart...
44 patents (USPTO):

Title: Hakon Hakonarson: Innovator in ADHD Research

Introduction

Hakon Hakonarson, based in Malvern, PA, is a prominent inventor known for his significant contributions to research on attention-deficit hyperactivity disorder (ADHD). With an impressive portfolio of 43 patents, he has pioneered various methods and compositions that aim to improve the diagnosis and treatment of ADHD and related conditions.

Latest Patents

Among Hakonarson's latest innovations is a patent focusing on the association of genetic variations to diagnose and treat ADHD. This work provides new compositions and methods aimed at enhancing the detection and management of the disorder. Additionally, he has developed a patent on nonselective metabotropic glutamate receptor activators for the treatment of ADHD, 22q deletion and/or duplication syndrome, and associated comorbidities. This application discusses the use of such activators, like fasoracetam, on individuals with specific genetic alterations in the metabotropic glutamate receptor (mGluR) network gene.

Career Highlights

Hakonarson has held significant positions in reputable organizations that underline his impact in the field of genetic research. Notably, he has worked at The Children's Hospital of Philadelphia, where he contributed to groundbreaking studies and clinical advancements. Additionally, his tenure at Decode Genetics Ehf has further solidified his standing as a leading expert in genetic research linked to ADHD.

Collaborations

Throughout his career, Hakonarson has collaborated with esteemed colleagues, including Charlly Kao and Jonathan Paul Bradfield. These collaborations have facilitated the exchange of innovative ideas and research, enhancing the potential for advancements in ADHD treatment and understanding.

Conclusion

Hakon Hakonarson's contributions to the fields of genetics and ADHD research exemplify the powerful intersection of innovation and healthcare. His extensive patent portfolio not only reflects his commitment to advancing medical science but also highlights the potential for future breakthroughs that could transform the way ADHD is diagnosed and treated.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…